765 related articles for article (PubMed ID: 31676858)
1. TIM3 comes of age as an inhibitory receptor.
Wolf Y; Anderson AC; Kuchroo VK
Nat Rev Immunol; 2020 Mar; 20(3):173-185. PubMed ID: 31676858
[TBL] [Abstract][Full Text] [Related]
2. Effects of immune checkpoint blockade on antigen-specific CD8
Ogando-Rivas E; Castillo P; Jones N; Trivedi V; Drake J; Dechkovskaia A; Candelario KM; Yang C; Mitchell DA
Microbiol Immunol; 2022 May; 66(5):201-211. PubMed ID: 35150167
[TBL] [Abstract][Full Text] [Related]
3. Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus.
Caraballo Cortés K; Osuch S; Perlejewski K; Pawełczyk A; Kaźmierczak J; Janiak M; Jabłońska J; Nazzal K; Stelmaszczyk-Emmel A; Berak H; Bukowska-Ośko I; Paciorek M; Laskus T; Radkowski M
J Viral Hepat; 2019 Aug; 26(8):942-950. PubMed ID: 30972915
[TBL] [Abstract][Full Text] [Related]
4. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
5. Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells.
Martín-Manzo MV; Lara C; Vargas-de-Leon C; Carrero J; Queipo G; Fonseca-Sanchez M; Mejia-Dominguez NR; Kershenobich D; Mummidi S; Zentella-Dehesa A; Hernandez J
Pathol Oncol Res; 2019 Jul; 25(3):1233-1243. PubMed ID: 30759303
[TBL] [Abstract][Full Text] [Related]
6. Expression of PD-1 and Tim-3 markers of T-cell exhaustion is associated with CD4 dynamics during the course of untreated and treated HIV infection.
Rallón N; García M; García-Samaniego J; Cabello A; Álvarez B; Restrepo C; Nistal S; Górgolas M; Benito JM
PLoS One; 2018; 13(3):e0193829. PubMed ID: 29518102
[TBL] [Abstract][Full Text] [Related]
7. The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.
Kandel S; Adhikary P; Li G; Cheng K
Cancer Lett; 2021 Jul; 510():67-78. PubMed ID: 33895262
[TBL] [Abstract][Full Text] [Related]
8. TIM-3 as a marker of exhaustion in CD8
Mohammadizad H; Shahbazi M; Hasanjani Roushan MR; Soltanzadeh-Yamchi M; Mohammadnia-Afrouzi M
Microb Pathog; 2019 Mar; 128():323-328. PubMed ID: 30660734
[TBL] [Abstract][Full Text] [Related]
9. Scrutinizing the Expression and Blockade of Inhibitory Molecules Expressed on T Cells from Acute Myeloid Leukemia Patients.
Abdolmaleki M; Mojtabavi N; Zavvar M; Vaezi M; Noorbakhsh F; Nicknam MH
Iran J Allergy Asthma Immunol; 2018 Jun; 17(3):265-273. PubMed ID: 29908544
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.
Roussel M; Le KS; Granier C; Llamas Gutierrez F; Foucher E; Le Gallou S; Pangault C; Xerri L; Launay V; Lamy T; Tartour E; Olive D; Fest T
Blood Adv; 2021 Apr; 5(7):1816-1829. PubMed ID: 33787861
[TBL] [Abstract][Full Text] [Related]
11. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
[TBL] [Abstract][Full Text] [Related]
12. Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
Natoli M; Hatje K; Gulati P; Junker F; Herzig P; Jiang Z; Davydov II; Germann M; Trüb M; Marbach D; Zwick A; Weber P; Seeber S; Wiese M; Lardinois D; Heinzelmann-Schwarz V; Rosenberg R; Tietze L; Mertz KD; Umaña P; Klein C; Codarri-Deak L; Kao H; Zippelius A
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319064
[TBL] [Abstract][Full Text] [Related]
13. Increased co-expression of PD1 and TIM3 is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer.
He X; Peng Y; He G; Ye H; Liu L; Zhou Q; Shi J; Fu S; Wang J; Zhou Z; Li W
J Transl Med; 2023 Oct; 21(1):717. PubMed ID: 37828574
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
Kim KJ; Lee HW; Seong J
J Gastroenterol Hepatol; 2021 May; 36(5):1357-1365. PubMed ID: 33217056
[TBL] [Abstract][Full Text] [Related]
15. Short Communication: Metformin Reduces CD4 T Cell Exhaustion in HIV-Infected Adults on Suppressive Antiretroviral Therapy.
Shikuma CM; Chew GM; Kohorn L; Souza SA; Chow D; SahBandar IN; Park EY; Hanks N; Gangcuangco LMA; Gerschenson M; Ndhlovu LC
AIDS Res Hum Retroviruses; 2020 Apr; 36(4):303-305. PubMed ID: 31731885
[TBL] [Abstract][Full Text] [Related]
16. CD8
Tao J; Han D; Gao S; Zhang W; Yu H; Liu P; Fu R; Li L; Shao Z
J Cell Mol Med; 2020 Jan; 24(1):1046-1058. PubMed ID: 31756785
[TBL] [Abstract][Full Text] [Related]
17. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
18. Significance of TIM3 expression in cancer: From biology to the clinic.
Solinas C; De Silva P; Bron D; Willard-Gallo K; Sangiolo D
Semin Oncol; 2019; 46(4-5):372-379. PubMed ID: 31733828
[TBL] [Abstract][Full Text] [Related]
19. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis.
Markwick LJ; Riva A; Ryan JM; Cooksley H; Palma E; Tranah TH; Manakkat Vijay GK; Vergis N; Thursz M; Evans A; Wright G; Tarff S; O'Grady J; Williams R; Shawcross DL; Chokshi S
Gastroenterology; 2015 Mar; 148(3):590-602.e10. PubMed ID: 25479137
[TBL] [Abstract][Full Text] [Related]
20. CD8+CD103+PD1+TIM3+ T cells in glioblastoma microenvironment correlate with prognosis.
Romagnoli G; D'Alessandris QG; Capone I; Tavilla A; Canini I; Lapenta C; Buccarelli M; Giordano M; Tirelli V; Sanchez M; Fragale A; Giannetti S; Di Bonaventura R; Lauretti L; Biffoni M; Ricci-Vitiani L; Pallini R; Gabriele L
Immunology; 2024 Feb; 171(2):198-211. PubMed ID: 37884280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
